Peripheral blood mononuclear cell dihydropyrimidine dehydrogenase activity in volunteers with and without diabetes mellitus

• Published in: Cancer chemotherapy and pharmacology 1996, Vol.37 (6), p.569-573
• Main Authors: FLEMING, G. F, VOKES, E. E, BUSE, J. B, MICK, R, FUSHAY, J, LEVITAN, D, DOLAN, M. E
• Format: Article
• Language: English
• Subjects: Adult; Aged; Animals; Biological and medical sciences; Body Mass Index; Diabetes Mellitus - blood; Diabetes Mellitus - enzymology; Dihydrouracil Dehydrogenase (NADP); Drug toxicity and drugs side effects treatment; Female; Humans; Leukocytes, Mononuclear - enzymology; Male; Medical sciences; Middle Aged; Miscellaneous (drug allergy, mutagens, teratogens...); Oxidoreductases - blood; Pharmacology. Drug treatments
• ISSN: 0344-5704; 1432-0843
• DOI: 10.1007/s002800050430

It has been reported that cancer patients with diabetes mellitus receiving a continuous infusion of 5-fluorouracil (5-FU) have more toxicity and higher plasma 5-FU levels that patients without diabetes mellitus. Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme in the catabolism of 5-FU. DPD activity in peripheral blood mononuclear cells has been reported to correlate inversely with 5-FU plasma levels in patients. We therefore undertook a study to compare the activity of DPD in peripheral blood mononuclear cells of human subjects with and without diabetes mellitus. The study groups comprised 43 volunteers with and 39 without diabetes mellitus, and peripheral blood mononuclear cell DPD activity was assayed on samples obtained between 8 a.m. and 11 a.m. DPD activity was not decreased in diabetic subjects. There was no relationship between DPD activity and gender body mass index, or race. There was a modest correlation between DPD activity and age (r=0.19, P =0.08). We conclude that increases in 5-FU-related toxicities in diabetics must be related to factors other than peripheral blood mononuclear cell DPD activity.